The KEYNOTE‐048 study has validated that pembrolizumab in combination with platinum and 5‐Fu is an effective first‐line treatment for recurrent or metastatic HNSCC in populations with a PD‐L1 combined positive score (CPS) of 20 or more, CPS of 1 or more, and in the total population. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.